| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary mechanism of action for 6'-O-trans-Feruloylnodakenin is attributed to its ability to scavenge free radicals due to the presence of hydroxyl groups. This antioxidant activity helps in mitigating oxidative stress in biological systems. As a coumarin glycoside, it may also interact with other targets involved in inflammation and neuroprotection.
|
|---|---|
| ln Vitro |
In vitro, 6'-O-trans-Feruloylnodakenin is used as a key compound for enzyme studies related to inflammation and neuroprotection. Its antioxidant activity, attributed to its ability to scavenge free radicals due to the presence of hydroxyl groups, has been characterized. It is a marker compound used for the HPLC fingerprint of N. forbesii, making it valuable for analytical and quality control applications.
|
| ln Vivo |
In vivo, 6'-O-trans-Feruloylnodakenin is used in model research related to inflammation and neuroprotection. Its antioxidant activity suggests it may have protective effects in animal models of oxidative stress, inflammation, and neurodegenerative diseases. However, specific in vivo efficacy data are not detailed in the available literature. Further studies are needed to evaluate its pharmacokinetics and efficacy.
|
| Enzyme Assay |
Typical in vitro assays for 6'-O-trans-Feruloylnodakenin include antioxidant assays such as DPPH and ABTS radical scavenging assays, where the compound is incubated with radical solutions at various concentrations and absorbance is measured at specific wavelengths. For enzyme studies, the compound is used as a substrate or inhibitor in assays measuring enzyme activity. It is also used as a marker compound in HPLC for fingerprint analysis of N. forbesii.
|
| Cell Assay |
Cellular assays for 6'-O-trans-Feruloylnodakenin typically involve treating cultured cells (e.g., neuronal cells, macrophages) with the compound at concentrations ranging from 1-100 µM for 24-48 hours. ROS levels are measured using fluorescent probes to assess antioxidant activity. Inflammatory markers such as NO, TNF-α, and IL-6 are measured by ELISA or Griess assay. Neuroprotective effects are assessed by measuring cell viability after exposure to oxidative stress or neurotoxic agents.
|
| Animal Protocol |
In vivo animal experiments for 6'-O-trans-Feruloylnodakenin are not detailed in the available literature. For neuroprotection studies, typical animal models include those for neurodegenerative diseases such as Alzheimer's or Parkinson's disease. For anti-inflammatory studies, models such as carrageenan-induced paw edema or LPS-induced systemic inflammation are used. The compound would be administered orally or intraperitoneally, and oxidative stress and inflammatory markers would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 6'-O-trans-Feruloylnodakenin are limited. As a coumarin glycoside with a molecular weight of 540.52 g/mol, it may be hydrolyzed in the intestine to release the aglycone, which may be absorbed. The compound's antioxidant properties suggest it may have beneficial effects in vivo. However, detailed ADME parameters are not available in the consulted sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for 6'-O-trans-Feruloylnodakenin are limited. As a natural coumarin glycoside, it is generally considered to have low toxicity. However, coumarins can have hepatotoxic potential at high doses. Standard laboratory safety precautions should be followed when handling the compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
Reports have indicated the discovery of 6'-Feruloylnodakenin in Hansenia forbesii, and relevant data are available for reference.
6'-O-trans-Feruloylnodakenin (Forbesoside) is a natural coumarin glycoside and a marker compound for the HPLC fingerprint of N. forbesii. It has antioxidant activity due to its ability to scavenge free radicals and is used in research on inflammation and neuroprotection. It is a research compound and is not approved for any clinical indication. |
| Molecular Formula |
C30H32O12
|
|---|---|
| Molecular Weight |
584.57
|
| Exact Mass |
584.189
|
| CAS # |
131623-14-8
|
| PubChem CID |
6439317
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.48g/cm3
|
| Boiling Point |
820.4ºC at 760mmHg
|
| Flash Point |
268.3ºC
|
| Vapour Pressure |
1.76E-28mmHg at 25°C
|
| Index of Refraction |
1.659
|
| LogP |
1.67
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
42
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O([C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])OC(/C(/[H])=C(\[H])/C2C([H])=C([H])C(=C(C=2[H])OC([H])([H])[H])O[H])=O)O1)O[H])O[H])O[H])C(C([H])([H])[H])(C([H])([H])[H])[C@@]1([H])C([H])([H])C2C([H])=C3C([H])=C([H])C(=O)OC3=C([H])C=2O1
|
| InChi Key |
AIKVOZSRVVMWGS-UEXLCRCOSA-N
|
| InChi Code |
InChI=1S/C30H32O12/c1-30(2,23-12-17-11-16-6-9-25(33)40-19(16)13-20(17)39-23)42-29-28(36)27(35)26(34)22(41-29)14-38-24(32)8-5-15-4-7-18(31)21(10-15)37-3/h4-11,13,22-23,26-29,31,34-36H,12,14H2,1-3H3/b8-5+/t22-,23-,26-,27+,28-,29+/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(2R)-7-oxo-2,3-dihydrofuro[3,2-g]chromen-2-yl]propan-2-yloxy]oxan-2-yl]methyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7107 mL | 8.5533 mL | 17.1066 mL | |
| 5 mM | 0.3421 mL | 1.7107 mL | 3.4213 mL | |
| 10 mM | 0.1711 mL | 0.8553 mL | 1.7107 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
